ANGPTL3 Gene Editing: Promise and Prudence

Advances in lipid biology and human genetics have progressively reshaped the understanding of atherosclerotic cardiovascular disease (ASCVD), moving the field beyond a narrow focus on LDL cholesterol (LDL-C) towards a more integrated view of atherogenic lipoprotein burden. While LDL-C remains a central therapeutic target, it is increasingly evident that triglyceride-rich lipoproteins and their remnants, together with apolipoprotein B (apoB)-containing particles across the lipoprotein spectrum, play a causal role in atherogenesis and residual cardiovascular risk.1,2 Within this evolving framework, angiopoietin-like protein 3 (ANGPTL3) has emerged as a pivotal regulator of lipid metabolism and a uniquely compelling therapeutic target.

ANGPTL3 is a hepatokine almost exclusively synthesised and secreted by the liver. Once in the circulation, it exerts systemic effects by inhibiting two key intravascular lipases: lipoprotein lipase (LPL), which governs the hydrolysis of triglycerides in chylomicrons and very-LDLs (VLDLs); and endothelial lipase, which modulates phospholipid hydrolysis in HDLs.3,4 Through this dual inhibitory action, ANGPTL3 influences plasma triglyceride levels, remnant lipoprotein accumulation, HDL metabolism and, indirectly but importantly, LDL-C concentrations.

Physiologically, ANGPTL3 plays a central role in energy partitioning and lipid trafficking. In states of energy sufficiency, increased ANGPTL3 activity limits peripheral triglyceride clearance by suppressing LPL, thereby facilitating lipid storage in adipose tissue. Conversely, reduced ANGPTL3 activity enhances LPL-mediated lipolysis, accelerates clearance of triglyceride-rich lipoproteins and reduces the pool of circulating apoB-containing particles available for conversion into LDL.5 This coordinated regulation positions ANGPTL3 as a nodal integrator linking hepatic lipid production, peripheral lipolysis and atherogenic lipoprotein burden.

Importantly, ANGPTL3-mediated lipid regulation operates largely independently of the LDL receptor pathway. This characteristic distinguishes ANGPTL3 from many traditional lipid targets and has major therapeutic implications, particularly for patients with familial hypercholesterolaemia. In such individuals, LDL receptor dysfunction limits the efficacy of statins and PCSK9 inhibitors, whereas ANGPTL3 inhibition lowers LDL-C by reducing VLDL secretion and enhancing remnant clearance upstream of LDL formation.6,7 This receptor-independent mechanism explains the robust LDL-C reductions observed with ANGPTL3-targeted therapies even in homozygous familial hypercholesterolaemia.

The strongest validation of ANGPTL3 as a therapeutic target derives from human genetics. Individuals carrying heterozygous or homozygous loss-of-function variants in ANGPTL3 exhibit a phenotype characterised by lifelong reductions in triglycerides, LDL-C, non-HDL cholesterol and apoB, a condition often referred to as familial combined hypolipidaemia.8 Large population-based sequencing studies have consistently demonstrated that these individuals have a substantially lower risk of ASCVD, without apparent deleterious metabolic or developmental consequences.9 These observations indicate strong causal inference, approximating lifelong randomised exposure.

Mendelian randomisation analyses further support a direct, causal relationship between ANGPTL3-mediated lipid lowering and reduced cardiovascular risk, reinforcing the concept that triglyceride-rich lipoproteins and their remnants are not merely markers but mediators of atherosclerosis.10 Collectively, these genetic data place ANGPTL3 among the most robustly validated lipid targets identified to date.

This genetic foundation has driven the development of multiple pharmacological strategies aimed at ANGPTL3 inhibition. Monoclonal antibodies such as evinacumab, as well as RNA-based approaches including antisense oligonucleotides and small interfering RNAs have demonstrated substantial reductions in triglycerides, LDL-C, non-HDL cholesterol and apoB across a range of dyslipidaemic phenotypes.11,12 However, these therapies require chronic administration and remain subject to the well-documented limitations of long-term adherence, tolerability and sustained access.

Against this background, in vivo gene editing of ANGPTL3 represents a conceptual escalation from reversible pharmacological modulation to permanent genetic alteration. By aiming to reproduce the naturally occurring, cardioprotective loss-of-function state, ANGPTL3 gene editing challenges existing paradigms of lipid management and raises fundamental questions regarding the future of cardiovascular prevention.

From Medication to Gene Editing

In this context, the Phase I trial of CTX310 reported by Laffin et al. marks a critical proof of concept.13 CTX310 is a lipid nanoparticle-encapsulated CRISPR–Cas9 therapy designed to induce loss-of-function mutations in hepatic ANGPTL3. In patients with refractory hypercholesterolaemia, hypertriglyceridemia or mixed dyslipidaemia, a single IV infusion produced dose-dependent reductions in circulating ANGPTL3 levels, accompanied by clinically meaningful decreases in LDL-C, triglycerides, non-HDL cholesterol and apoB.

At the highest dose tested, LDL-C and triglyceride reductions approached 50% and 55%, respectively, within 60 days, magnitudes comparable to those achieved with the most potent existing lipid-lowering therapies. Importantly, these effects were observed on top of maximally tolerated background treatment, underscoring the additive and receptor-independent nature of ANGPTL3 disruption.

From a pathophysiological standpoint, the ability of ANGPTL3 gene editing to simultaneously lower LDL-C and triglycerides is particularly compelling. Contemporary models of atherogenesis emphasise the central role of apoB-containing particles across the entire lipoprotein spectrum, including triglyceride-rich remnants.1,2 A therapeutic strategy capable of durably reducing total apoB burden therefore aligns closely with current concepts of residual cardiovascular risk.

Irreversibility Means Caution

As expected for a first-in-human Phase I study, the primary objective of the CTX310 trial was safety. No dose-limiting toxic effects related to the intervention were observed, and adverse events were predominantly mild to moderate infusion-related reactions consistent with lipid nanoparticle delivery. Transient aminotransferase elevations occurred in a single participant and resolved without clinical sequelae. One death occurred several months after treatment and was deemed unrelated; nevertheless, this highlights the importance of caution in interpreting early safety data in small cohorts.13

Crucially, gene editing introduces an element absent from all current lipid-lowering therapies: irreversibility. Regulatory guidance appropriately mandates long-term follow-up (up to 15 years) for in vivo genome-editing interventions, reflecting the potential for late-emerging adverse effects. Once the genome has been altered, therapeutic reversibility is not an option, and future advances cannot easily be layered onto an irrevocably modified biological system.

These considerations underscore the importance of careful patient selection. Individuals with homozygous familial hypercholesterolaemia, severe refractory hypercholesterolaemia or extreme hypertriglyceridaemia (conditions associated with a high lifetime ASCVD risk and limited therapeutic alternatives) may be the most appropriate initial candidates, in whom the benefit–uncertainty balance is most favourable (Figure 1).

Figure 1: ANGPTL3 Gene Editing: Promise and Prudence.

In vivo CRISPR–Cas9-mediated disruption of ANGPTL3 aims to reproduce the naturally occurring loss-of-function state associated with lifelong reductions in triglycerides, LDL cholesterol, and apolipoprotein B-containing lipoproteins. While this one-time intervention offers the potential for durable, LDL receptor-independent lipid lowering (promise), its irreversible nature, uncertain long-term safety and ethical considerations highlight the need for careful patient selection and prolonged follow-up (prudence). Created in BioRender. https://BioRender.com/q52ysih

Long-term Lipid Management

Beyond its biological novelty, ANGPTL3 gene editing challenges prevailing paradigms of chronic cardiovascular prevention. Long-term adherence to lipid-lowering therapy remains suboptimal, with substantial discontinuation rates observed within the first year of treatment and progressive attrition over time. A one-time intervention capable of durable lipid modification could, theoretically, eliminate adherence as a determinant of therapeutic success.

However, such potential advantages must be balanced against economic, ethical and health system considerations. Gene-editing therapies are likely to carry substantial upfront costs, requiring new payment models focused on the long-term benefit rather than lifelong use. Moreover, integration with established preventive strategies rather than replacement will be essential to avoid premature extrapolation beyond populations with the greatest unmet need.

Conclusion

ANGPTL3 gene editing represents a convergence of genetic insight, molecular precision and therapeutic ambition. The early clinical experience with CTX310 demonstrates that permanent disruption of a central lipid regulator is feasible and capable of producing profound reductions in both LDL-C and triglycerides. At the same time, the irreversible nature of genome editing demands a level of prudence commensurate with its promise.

As cardiology stands at the threshold of a new era, ANGPTL3 gene editing offers a compelling glimpse into the future of lipid management, one in which atherogenic lipoprotein burden may be durably reduced by design rather than continuously suppressed by medication. Whether this approach will, ultimately, redefine cardiovascular prevention will depend not only on efficacy but also on long-term safety, ethical stewardship and disciplined clinical implementation.